ライフサイエンスコーパス: body surface area

1 c MRI-assessed cardiac index (cardiac output/body surface area).

2 rn or sham injury (approximately 12.5% total body surface area).

3 n 63 patients with major burns (>/=15% total body surface area).

4 evaluated with cardiac MRI and normalized to body surface area.

5 pression, particularly in those with smaller body surface area.

6 l vitiligo that involved 15% to 50% of total body surface area.

7 gen, panel reactive antibody >10%, and lower body surface area.

8 5) in end-systolic volume indexed (ESVi) to body surface area.

9 Volumetric measurements were indexed for body surface area.

10 her the hemodynamic measures were indexed to body surface area.

11 njection of 740 MBq (20 mCi) per 1.7 m(2) of body surface area.

12 n the basis of correlation existing with the body surface area.

13 id not correlate with age when normalized to body surface area.

14 rsal scald burn injury covering 30% of total body surface area.

15 ight, lean body weight, body mass index, and body surface area.

16 keratinocyte hyperplasia and an increase in body surface area.

17 h ischemic mitral regurgitation of identical body surface area.

18 fat mass, resting metabolic rate (RMR), and body surface area.

19 er syndrome must be evaluated in relation to body surface area.

20 ll received miglustat at a dose adjusted for body surface area.

21 ntegra is safe to use in burns of <20% total body surface area.

22 t of weight per moisturizer used for a given body surface area.

23 emales before but not after normalization to body surface area.

24 iligo involves an estimation of the affected body surface area.

25 y inverted after indexation of RV volumes to body surface area.

26 gnosed AD involving at least 5% of the total body surface area.

27 jected to a full-thickness burn of 30% total body surface area.

28 enting with marked systemic features and low body surface area.

29 dmitted with burns covering 52% of his total body surface area.

30 (GFR) was 18 ml per minute per 1.73 m(2) of body-surface area.

31 ere was no correlation between clearance and body-surface area.

32 ociated with weight (0.02 mm/kg; P=0.01) and body surface area (1.1 mm/m(2); P<0.001).

33 1 +/- 5.10 g [p = 0.012]) and LVM indexed to body surface area (-1.32 +/- 2.84 g/m(2) vs. placebo gro

34 of LAV is currently performed by indexing to body surface area(1) (BSA(1)).

35 Magna/Magna Ease valves were smaller (median body surface area, 1.42 versus 1.93 m(2); P=0.002) and y

36 olume (left ventricular end-diastolic volume/body surface area, 104+/-13 and 69+/-18 mL/m(2); P<0.001

37 .001; right ventricular end-diastolic volume/body surface area, 110+/-22 and 66+/-16 mL/m(2); P<0.001

38 7 burn patients (mean age, 26.9 years; total body surface area, 16.1%) received 415 laser sessions (2

39 llitus (1.45 [1.39-1.51]), obesity in women (body surface area 2.2 versus 1.8: 1.44 [1.35-1.53]), fem

40 ence in age (65+/-10 versus 59+/-13; P=0.5), body surface area (2.0+/-0.2 versus 2.0+/-0.2 m(2); P=0.

41 (SD) athlete height was 200.2 (8.8) cm; mean body surface area, 2.38 (0.19) m2.

42 Patients with lower burn severity (total body surface area, 20-30%) express similar metabolic alt

43 than those with hypertension (LA volume max/ body surface area 30.2+/-6.6 versus 33.0+/-9.0 mL/m(2);

44 icipants with psoriasis affecting 3% or more body surface area, 33 of 63 (52%) in Group 1 and three o

45 /-10 g/m(2); P<0.001; right ventricular mass/body surface area, 36+/-7 and 24+/-5 g/m(2); P<0.001) an

46 29%]) or based on body weight (10 [48%]) and body surface area (4 [19%]).

47 ease), left ventricular (LV) mass indexed to body surface area (51% increase), and LV shortening frac

48 ith an average burn size of 73 +/- 15% total body surface area (71 +/- 15% full-thickness burn) were

49 edian age 40 years, median burn size 6.0% of body surface area), 71% were men and 76% were White.

50 ight ventricular mass (left ventricular mass/body surface area, 96+/-13 and 62+/-10 g/m(2); P<0.001;

51 iated with a 0.32-g/m(2) increase in LV mass/body surface area, a 0.43-mL/m(2) decrease in stroke vol

52 mensions, expressed as z scores adjusted for body-surface area, absolute dimensions, and changes in d

53 easurements were corrected for age, sex, and body surface area according to reference data and progno

54 rapy at a dose of 375 mg per square meter of body-surface area administered every 2 months for 3 year

55 mpared rituximab (375 mg per square meter of body-surface area administered once a week for 4 weeks)

56 reased in a stepwise fashion with increasing body surface area affected by PsO (P for trend <0.001).

57 8-32 years]) were all male with an estimated body surface area affected with RDEB of 4% to 30%.

58 evere psoriasis defined by 3% or more of the body surface area affected.

59 evere disease) and with 10% or more of their body-surface area affected by psoriasis to receive broda

60 ace area before vs. 58.9 +/- 17.5 mL/min per body surface area after therapy; P = 0.22); however, 3 p

61 , full-thickness burn size (FTBS, percentage body surface area), age, inhalation injury, sex, and fun

62 Total body surface area, age, and inhalation injury had signif

63 apy using verteporfin at a dose of 6 mg/m(2) body surface area and 689 nm diode laser at an intensity

64 lied with verteporfin at a dose of 6 mg/m(2) body surface area and a 689 nm diode laser for 83 second

65 Great vessel areas correlated well with body surface area and age in controls and reference Z-sc

66 unilateral pectoralis muscle mass indexed to body surface area and attenuation (approximated by mean

67 mited disease to involvement of 30% of their body surface area and had evidence of pulmonary sarcoido

68 th burns covering more than 20% of the total body surface area and required at least one surgical int

69 es in end-diastolic volume indexed (EDVi) to body surface area and the ejection fraction (EF).

70 eters corresponding to pesticide deposition, body surface area and weight, surface-to-body transfer e

71 of 700 mg of carboplatin per square meter of body-surface area and 750 mg of etoposide per square met

72 30.0 to 89.9 ml per minute per 1.73 m(2) of body-surface area and then randomly assigned them to rec

73 erapy (melphalan, 140 mg per square meter of body-surface area) and autologous stem-cell transplantat

74 ive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent

75 ceive bortezomib (1.3 mg per square meter of body-surface area) and dexamethasone (20 mg) alone (cont

76 ndence after TP-IAT: (1) male sex, (2) lower body surface area, and (3) higher total IEQ per kilogram

77 ea, a 0.43-mL/m(2) decrease in stroke volume/body surface area, and a 0.21% decrease in LVEF.

78 hysiology and Chronic Health Evaluation III, body surface area, and age, sarcopenia index was indepen

79 re independent of age when dose is scaled to body surface area, and ESA resistance is associated with

80 sociations of age, body length, body weight, body surface area, and heart rate on PAAT were investiga

81 Age, sex, body surface area, and high-level endurance training wer

82 sions, parameters of body size (body weight, body surface area, and organ circumference) and gestatio

83 mass and function after controlling for age, body surface area, and sex.

84 malizing to body weight, lean body mass, and body surface area, and simplified measurements were comp

85 starting dose of everolimus depended on age, body-surface area, and concomitant use of cytochrome 3A4

86 -weekly cycles of paclitaxel [175 mg/m(2) of body surface area] and carboplatin [area under the curve

87 Ascending aortic diameters normalized to body surface area (aortic size index) were significantly

88 , days in intensive care unit, sex, age, and body surface area at evaluation.

89 in the Psoriasis Area and Severity Index and body surface area at the end of treatment.

90 ity alleles presented a greater reduction in body surface area at the intermediate point, which remai

91 sed LV end-diastolic volume [EDV] indexed to body surface area) at baseline were excluded.

92 Indexing hemodynamic measurements to body surface area attenuates the effects of BMI.

93 atients with aortic valve area normalized to body surface area (AVA/BSA) <0.6 cm(2)/m(2); yet, this c

94 On the basis of AVA-indexed-to-body surface area (AVAi) and MG, patients were categoriz

95 e or after therapy (64.2 +/- 16.5 mL/min per body surface area before vs. 58.9 +/- 17.5 mL/min per bo

96 Small patients with a body-surface area below 0.7 m now have access to the ped

97 0 [95% CI, 2.2-22.8]; p < 0.001), a detached body surface area between 10% and 29% (odds ratio, 3.7 [

98 s in absolute and adjusted GS (corrected for body surface area) between 1 and 12 months after transpl

99 effective diameters at each level to patient body surface area (BSA) and sex.

100 scores for common measurements adjusted for body surface area (BSA) and stratified by age, sex, race

101 ss index (BMI; weight (kg)/height (m)2), and body surface area (BSA) at ages 7-13 years and birth wei

102 values for FAC, TAPSE, and TAPSE indexed to body surface area (BSA) decreased over time (P=0.03 for

103 Recorded variables included maximal body surface area (BSA) detachment, SCORTEN (Score of To

104 l dose of 2.2 x 10(11) platelets/transfusion/body surface area (BSA) do not affect any bleeding grade

105 udies to human studies, we suggest using the body surface area (BSA) normalization method.

106 Body surface area (BSA) of vitiligo lesions.RESULTS Pati

107 According to donor/recipient body surface area (BSA) ratio, patients were stratified

108 Body surface area (BSA) scaling has been used for prescr

109 xtensive cutaneous disease involving >90% of body surface area (BSA) suffered from severe symptoms re

110 nalysis, log-creatinine, sex, age, race, and body surface area (BSA) were significantly associated wi

111 Ratios of R/D body surface area (BSA) were used to estimate nephron di

112 xceptionally severe psoriasis at entry (>42% body surface area (BSA)) had a significantly increased r

113 2,044 participants had mild psoriasis (</=2% body surface area (BSA)), 1,377 had moderate psoriasis (

114 ncer was higher for participants with a high body surface area (BSA), great height, or excess weight

115 Body surface area (BSA)-adjusted chronic kidney disease

116 sage of the radiopharmaceutical according to body surface area (BSA).

117 , weight, height, body mass index (BMI), and body surface area (BSA).

118 ncreased median end-diastolic volume (100 ml/body surface area [BSA](1.3) vs. 82 ml/BSA(1.3); p = 0.0

119 stage II (end-diastolic volume [milliliters]/body surface area [BSA](1.3), end-systolic volume [milli

120 aluated whether the effect of clinical (age, body surface area [BSA], chronic kidney disease [CKD], a

121 6], p = nonsignificant), percentage of total body surface area burn (34 [20-52] vs. 34 [23-50], p = n

122 d MBL null mice were resistant to a 5% total body surface area burn alone or s.c. infection with P. a

123 Animals received 30% total body surface area burn followed by topical application o

124 0% EtOH 4 h before approximately 12.5% total body surface area burn or sham injury.

125 hours after injury, and more than 20% total body surface area burn requiring at least 1 surgical int

126 hty-nine children sustaining a >or=40% total body surface area burn were divided into females (n = 76

127 Burned children (n = 235) with >40% total body surface area burn were randomized (block randomizat

128 12 male pediatric burn patients (>30% total body surface area burn) and 12 young, healthy male subje

129 ed the varying effects of patient age, total body surface area burn, and inhalation injury on the pro

130 Children, 4-18 yrs old, with total body surface area burned > or =40% and who arrived withi

131 owed that a burn size of more than 60% total body surface area burned (an increase from 40% a decade

132 urn care setting, adults with over 40% total body surface area burned and children with over 60% tota

133 area burned and children with over 60% total body surface area burned are at high risk for morbidity

134 of 612 burned children [52% +/- 1% of total body surface area burned, ages 0.5-14 years (boys); ages

135 ome after controlling for age, gender, total body surface area burned, and inhalation injury (hazard

136 Age, total body surface area burned, and inhalation injury were als

137 +/- 15 years old and with 38% +/- 14% total body surface area burned, underwent an oral glucose tole

138 le organ failure was approximately 60% total body surface area burned.

139 tcomes was lower, at approximately 40% total body surface area burned.

140 er than 18 years or with more than 20% total body surface area burns (TBSA) burns were excluded.

141 nts (>/=16 years old) with 20% or more total body surface area burns recruited from 6 US burn centers

142 hours after injury, and more than 20% total body surface area burns requiring at least one surgical

143 hildren 4 to 16 years of age with >40% total body surface area burns were enrolled in a double-blind,

144 pediatric patients with more than 30% total body surface area burns were randomized to control (n =

145 -four pediatric patients with over 40% total body surface area burns were studied for 24 months after

146 escribe a 22-year-old soldier with 19% total body surface area burns, polytrauma, and sequence- and c

147 was admitted to the burn unit with 50% total body surface area burns.

148 tients, including 1476 with burns >20% total body surface area, by presence of AKI.

149 Cardiac output was indexed to body surface area (cardiac index [CI]) for all analyses.

150 zation, and echocardiography) and indexed to body surface area (cardiac index [CI]).

151 r were divided into two cohorts according to body-surface area (cohort 1, <0.7 m(2); cohort 2, 0.7 to

152 full-thickness thermal injury (30% of total body surface area), cold stress (4 degrees C for 24 h),

153 d mild, moderate, or severe disease based on body surface area criteria.

154 n Renal Disease formula result multiplied by body surface area divided by 1.73 m(2)) and the presence

155 ce (n=121) of methotrexate (40-60 mg/m(2) of body surface area), docetaxel (30-40 mg/m(2)), or cetuxi

156 ose of 0.75 (adjusted to 0.5 to 1.0) g/m2 of body surface area every 4 weeks for 6 months.

157 ne (at a dose of 1000 mg per square meter of body-surface area every 3 weeks and nivolumab-matched pl

158 axel (at a dose of 75 mg per square meter of body-surface area every 3 weeks for six cycles) or ADT a

159 usly at a dose of 175 mg per square meter of body-surface area every 3 weeks, plus carboplatin (dose

160 axel, at a dose of 75 mg per square meter of body-surface area every 3 weeks.

161 taxel at a dose of 75 mg per square meter of body-surface area every 3 weeks.

162 o nab-paclitaxel (125 mg per square meter of body-surface area) followed by gemcitabine (1000 mg per

163 g monthly IV cyclophosphamide at 750 mg/m(2) body surface area for 6 months followed by quarterly IV

164 e) and paclitaxel (50 mg per square meter of body-surface area) for 5 weeks and concurrent radiothera

165 , 1x10(6), or 3x10(6) IU per square meter of body-surface area) for 8 weeks.

166 [eGFR] of <5 ml per minute per 1.73 m(2) of body-surface area from baseline) and a decrease in the e

167 efore receiving an approximately 12.5% total body surface area full thickness burn.

168 counted for total burn size (TBS, percentage body surface area), full-thickness burn size (FTBS, perc

169 arged LA was defined as a LA size indexed to body surface area > or =2.4 cm/m2.

170 Patients with LVH (LVM/body surface area >/=116 and >/=96 g/m(2) in men and wom

171 hysician's Global Assessment score >/=3 with body surface area >10%).

172 th imatinib dosed at 300 mg twice a day (for body-surface area > or = 1.5 m(2)).

173 rations as patients with larger burns (total body surface area, >/= 30%).

174 ft ventricular mass, adjusted for changes in body surface area, had disproportionately decreased by 1

175 imum aortic-root-diameter z score indexed to body-surface area (hereafter, aortic-root z score) over

176 l ventilation had a larger baseline detached body surface area, higher Logistic Organ Dysfunction sco

177 o monitor accurately and easily the affected body surface area in a standardized way.

178 ty as objectively determined by the affected body surface area in both unadjusted and adjusted analys

179 rdial infarction (1.24 [1.08-1.42]), and low body surface area in men (1.22 [1.14-1.30]).

180 VESVI was 41.2+/-20.0 ml per square meter of body-surface area in the CABG-alone group and 43.2+/-20.

181 ients was 46.1+/-22.4 ml per square meter of body-surface area in the CABG-alone group and 49.6+/-31.

182 ere 68 and 70 ml per minute per 1.73 m(2) of body-surface area in the development and validation data

183 ients was 54.6+/-25.0 ml per square meter of body-surface area in the repair group and 60.7+/-31.5 ml

184 and efficacy of 32 doses of BTZ (1.3 mg/m of body surface area) in 10 highly sensitized kidney transp

185 ] of 20 to 45 ml per minute per 1.73 m(2) of body-surface area) in a 1:1:1:1 ratio to receive placebo

186 ant trend, independent of age, toward larger body surface area-indexed ascending aortic diameters wit

187 and (3) the echocardiographically measured, body surface area-indexed, effective orifice area (EOAi

188 twice daily) or dacarbazine (1000 mg/m(2) of body surface area intravenously every 3 weeks).

189 or dacarbazine (1000 mg per square meter of body-surface area intravenously every 3 weeks).

190 moderate-to-severe chronic plaque psoriasis (body surface area involvement >/=10%, Physician's Global

191 ab, P = .005; and AHA, P = .006), extensive body surface area involvement (ssDNA ab, P = .01; and AN

192 Greater body surface area involvement was associated with poorer

193 ic records of patients with either SJS (<30% body surface area involvement) or TEN (> = 30% involveme

194 ore baseline (randomisation), 10% or greater body-surface area involvement at both screening and base

195 bility of its use in large burns (>50% total body surface area), its effects on postburn hypermetabol

196 Left atrial volume indexed to body surface area (LA index) was 55 +/- 26 ml/m(2) (<40

197 ation therapy exposure, younger age, smaller body-surface area, longer treatment exposure, and more s

198 hysician's Global Assessment score </=3 with body surface area </=10%) or severe (worst Physician's G

199 or primary outcomes: LV end-diastolic volume/body surface area, LV ejection fraction, LV end-diastoli

200 adius/wall thickness; LV end-systolic volume/body surface area, LV longitudinal strain rate, and LV e

201 onance imaging-determined LVM was indexed to body surface area (LVM index); in the LVH[-] group, LVM

202 ived 24 mg of adalimumab per square meter of body-surface area (maximum dose, 40 mg) subcutaneously e

203 ved intravenous infusion of IdU (200 mg/m(2) body surface area; maximum dose, 400 mg) over a 30-minut

204 in burn size (70 +/- 5% vs. 74 +/- 4% total body surface area), mortality (40% vs. 30%), and length

205 and 1242 women) aged 23.1+/-5.7 years, with body surface area of 1.9+/-0.2 m(2) and 8.9+/-4.9 years

206 57.1 and 53.6 years, respectively, P<0.0001; body surface area of 2.4 and 2.1 m(2), respectively, P<0

207 Fifty-four patients with burns to total body surface area of greater than or equal to 15%, intub

208 at a dose of 20 to 30 mg per square meter of body-surface area on a continuous dosing schedule (in 28

209 ing of docetaxel (100 mg per square meter of body-surface area on day 1), docetaxel (75 mg per square

210 omib at a dose of 1.3 mg per square meter of body-surface area on days 1, 4, 8, and 11).

211 eive 90 mg of paclitaxel per square meter of body-surface area on days 1, 8, and 15 every 4 weeks, ei

212 ion of etoposide (100 mg per square meter of body-surface area on days 2 to 4), doxorubicin (40 mg pe

213 001) even after adjustment for their smaller body surface area or aortic annular area (both P<0.0001)

214 R of 25 to 65 ml per minute per 1.73 m(2) of body-surface area or 56 to 65 years of age with an estim

215 d a GFR of 60 ml per minute per 1.73 m(2) of body-surface area or higher, 32.1% had hypertension, and

216 r >/=upper 90th percentile for age, sex, and body surface area) or not enlarged; the hazard of an adv

217 n [AUC 5 or 6] and paclitaxel 175 mg/m(2) of body surface area) or the same chemotherapy regimen plus

218 the standard dose (45 mg per square meter of body-surface area) or a high dose (90 mg per square mete

219 ving cisplatin (>/=70 mg per square meter of body-surface area) or cyclophosphamide-doxorubicin.

220 ither pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter)

221 ous dacarbazine (1000 mg per square meter of body-surface area) or paclitaxel (175 mg per square mete

222 ubicin-based chemotherapy (90 mg per m(2) of body surface area over 3 days, by infusion).

223 0 +/- 6.3 to 75.5 +/- 6.3 mL.min(-1) . m(-2) body surface area (P < 0.01), because of improvements in

224 After adjusting for age (P = .090), body surface area (P = .073), and sex (P = .005), pulmon

225 f prior Puestow procedure (P = 0.018), lower body surface area (P = 0.048), higher islet equivalents

226 with severe P-PtM had a significantly larger body surface area (P<0.0001), higher mean gradient (P<0.

227 At baseline, AA women had higher body-surface area (P < .0001) and lower WBC (P = .0009).

228 39 versus 112+/-33 mL/BSA(1.3), where BSA is body surface area; P=0.02).

229 agnetic resonance measures for age, sex, and body surface area, particularly given the changing demog

230 tered at a dose of 20 mg per square meter of body-surface area per day for 10 consecutive days in mon

231 of fluorouracil (500 mg per square meter of body-surface area per day) during fractions 1 to 5 and 1

232 ovir suppression (300 mg per square meter of body-surface area per dose orally, three times daily for

233 ial of rituximab (375 mg per square meter of body-surface area per week for 4 weeks) as compared with

234 imab at a dose of 375 mg per square meter of body-surface area per week for 4 weeks, with two intrave

235 10.9 and 15.6 ml per minute per 1.73 m(2) of body-surface area per year in the eprodisate and the pla

236 alan at a dose of 200 mg per square meter of body-surface area plus autologous stem-cell transplantat

237 ubicin (60, 75, or 90 mg per square meter of body-surface area) plus cyclophosphamide (600 mg per squ

238 axel at a dose of 175 mg per square meter of body-surface area, plus carboplatin at an area under the

239 latin at a dose of 50 mg per square meter of body-surface area, plus paclitaxel at a dose of 135 or 1

240 y with age (r=0.848), body length (r=0.871), body surface area (r=0.856), and body weight (r=0.825) a

241 related with the degree of RVH (RV thickness/body surface area; r(2)=0.838 and r(2)=0.818, respective

242 ricular indexed end-diastolic volume >125 mL/body surface area raised to the 1.3 power was associated

243 ormulas (Lin or Vauthey using body weight or body surface area) rather than Urata's.

244 or 4.4x10(11) platelets per square meter of body-surface area, respectively), when morning platelet

245 -1.51+/-1.33 ml per minute per 1.73 m(2) of body-surface area, respectively.

246 ce: Standard dosing of chemotherapy based on body surface area results in marked interpatient variati

247 Corrected for age, sex, and body surface area, right ventricular end-systolic volume

248 Body surface area seems to be appropriate for indexation

249 of stroke between 11 and 365 days were small body surface area, severe aortic calcification, and fall

250 nt confirmed and then subjected to 30% total body surface area steam burn injury.

251 ither PEG alfa-2a (PEG-2a; 180 mug/1.73 m(2) body surface area, subcutaneously each week; n = 55) and

252 LVEF of >/=50% but stroke volume indexed to body surface area (SVi) of </=35 ml m(-2); and 629 (54%)

253 After adjusting for age, race, body surface area, systolic blood pressure, history of h

254 lly injured, as demonstrated by mean % total body surface area (TBSA) (41.2 +/- 18.3 for adults and 5

255 included in the analysis, with a mean total body surface area (TBSA) burn of 7.2% and a mean age of

256 ll transfusion strategy in 20% or more total body surface area (TBSA) burn patients.

257 ned adult patients with burns over 20% total body surface area (TBSA) burn were prospectively randomi

258 ty, even after adjusting for age and % total body surface area (TBSA) burn.

259 jects is 42.5 +/- 16.0 years, the mean total body surface area (TBSA) burned is 18.5 +/- 16.4%, and t

260 Exact skin quantities (cm(2)) and total body surface area (TBSA) percentages were calculated usi

261 y are receiving more fluid per percent total body surface area (TBSA) than in the past.

262 ts with burns of at least 30% of their total body surface area (TBSA).

263 verely burned pediatric patients [>30% total body surface area (TBSA)], who received no anabolic drug

264 45 mm, lowered toward 40 in females with low body surface area, TGFBR2 mutation, and severe extra-aor

265 n multivariate regression analyses including body surface area, the 3 different MVA methods, and dPme

266 The animals were exposed to 40% total body surface area third degree skin flame burn and 48 br

267 an injury group without treatment (40% total body surface area third-degree burn and 48 breaths of co

268 rn and smoke inhalation injury (40% of total body surface area, third-degree flame burn; 4 x 12 breat

269 18 of these 92 products, a minimum weight or body surface area threshold is recommended for adolescen

270 f at least 30 ml per minute per 1.73 m(2) of body-surface area to receive either empagliflozin (at a

271 sed cardiac index (cardiac output divided by body surface area) to incident all-cause dementia and Al

272 R], 15 to <30 ml per minute per 1.73 m(2) of body-surface area) to bardoxolone methyl, at a daily dos

273 ate [GFR] >60 ml per minute per 1.73 m(2) of body-surface area) to either a standard blood-pressure t

274 FR], 25 to 60 ml per minute per 1.73 m(2) of body-surface area) to receive an ACE inhibitor (lisinopr

275 lly, at a dose of 3.0 mg per square meter of body-surface area, to achieve a trough concentration of

276 Propensity matching based on age, sex, body surface area, total fluoroscopy time, and total acq

277 the eTLV (calculated as -794.41 + 1267.28 x body surface area) using volumetric data (cm) and clinic

278 Renal blood flow indexed to body surface area was 244 mL/min/m2 (range 165-662) in s

279 The total body surface area was 33% (22%-52%).

280 e 74% of patients in whom at least 3% of the body surface area was affected by psoriasis at baseline,

281 PASI) in patients in whom at least 3% of the body surface area was affected by psoriasis at baseline,

282 METHODS AND LA volume indexed to body surface area was measured by cardiovascular magneti

283 h age, height, and weight, normalization for body surface area was most efficient in removing the eff

284 less than 60 ml per minute per 1.73 m(2) of body-surface area was higher with the cystatin C-based e

285 terquartile range) age, body mass index, and body surface area were 68 (57-77) years, 28 (24-34) kg/m

286 he Psoriasis Area and Severity Index and the body surface area were assessed at baseline and at treat

287 ney morphological characteristics indexed to body surface area were associated inversely and independ

288 perative computed tomographic scans and (ii) body surface area were available entered the study.

289 Dimensions corrected by body surface area were higher in men than in women at th

290 patients with burns over 30% of their total body surface area were included in this trial.

291 3DE LA volumes indexed by body surface area were similar in men and women and incr

292 Age and body surface area were similar in the 4 valve morphology

293 Age, left ventricular mass, and body surface area were the main predictors of aortic dim

294 (mL/kg) and per percentage burn (mL/kg/total body surface area) were also lower for the computer deci

295 ase (eGFR <60 ml per minute per 1.73 m(2) of body-surface area) were analyzed with the use of linear

296 ne dose of 4.3 g or more per square meter of body-surface area (which has been associated with premat

297 Cluster 1 had high SASSAD scores and body surface areas with the highest levels of pulmonary

298 ease in the aortic-root diameter relative to body-surface area with either treatment.

299 VESVI was 52.6+/-27.7 ml per square meter of body-surface area with mitral-valve repair and 60.6+/-39

300 e, 9-40 years) and were indexed according to body surface area, with internal validation (R(2) = 0.84